Center for Biomedical Engineering and Technology and Department of Physiology.
Department of Medicine and Division of Cardiology, University of Maryland Baltimore, School of Medicine, Baltimore, Maryland, USA.
J Clin Invest. 2020 Mar 2;130(3):1112-1115. doi: 10.1172/JCI135759.
The ATP-sensitive K+ channel (KATP) is formed by the association of four inwardly rectifying K+ channel (Kir6.x) pore subunits with four sulphonylurea receptor (SUR) regulatory subunits. Kir6.x or SUR mutations result in KATP channelopathies, which reflect the physiological roles of these channels, including but not limited to insulin secretion, cardiac protection, and blood flow regulation. In this issue of the JCI, McClenaghan et al. explored one of the channelopathies, namely Cantu syndrome (CS), which is a result of one kind of KATP channel mutation. Using a knockin mouse model, the authors demonstrated that gain-of-function KATP mutations in vascular smooth muscle resulted in cardiac remodeling. Moreover, they were able to reverse the cardiovascular phenotypes by administering the KATP channel blocker glibenclamide. These results exemplify how genetic mutations can have an impact on developmental trajectories, and provide a therapeutic approach to mitigate cardiac hypertrophy in cases of CS.
ATP 敏感性钾通道(KATP)由四个内向整流钾通道(Kir6.x)孔亚基与四个磺酰脲受体(SUR)调节亚基组成。Kir6.x 或 SUR 突变导致 KATP 通道病,反映了这些通道的生理作用,包括但不限于胰岛素分泌、心脏保护和血流调节。在本期 JCI 中,McClenaghan 等人研究了一种通道病,即坎图综合征(CS),这是一种 KATP 通道突变的结果。作者使用基因敲入小鼠模型,证明血管平滑肌中功能获得性 KATP 突变导致心脏重构。此外,他们通过给予 KATP 通道阻滞剂格列本脲来逆转心血管表型。这些结果说明了基因突变如何影响发育轨迹,并为减轻 CS 情况下的心脏肥大提供了一种治疗方法。